{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-157992","form_type":"8-K","ticker":null,"cik":"0001850079","company_name":"Telesis Bio Inc.","filed_at":"2023-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.223274+00:00","generated_at":"2026-06-14T10:49:16.082358+00:00","sec_items":["1.01","3.03","3.02","5.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Telesis Bio raises $28M via convertible preferred, cuts 2023 revenue guidance to ~$35M","bullets":["Gross proceeds of $28.0M from redeemable convertible preferred; warrants could add $46.2M if cash exercised.","2023 revenue guidance lowered to approximately $35M; operating expenses ~$55M; gross margin 57% unchanged.","CEO states goal to approach profitability in 2024 timeframe; financing led by Novalis LifeSciences.","Paul Meister of Novalis appointed to board of directors, expanding board from seven to eight.","Private placement expected to close June 2, 2023; investors include Northpond, BroadOak, and CEO affiliate M-185."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-157992","json":"https://secwatch.observer/filing/0001193125-23-157992.json","markdown":"https://secwatch.observer/filing/0001193125-23-157992.md","text":"https://secwatch.observer/filing/0001193125-23-157992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850079/000119312523157992/0001193125-23-157992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850079/000119312523157992/d514788d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T10:49:16.082358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"011e61ab3a","claim":"Paul Meister was appointed as Director at Telesis Bio Inc..","evidence_excerpt":"appointed Paul Meister, a partner at Novalis LifeSciences LLC, as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850079/000119312523157992/0001193125-23-157992-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1e7ece4bd66ebd157daf718f6ab9b5ae35eec39d","claim":"Telesis Bio Inc.: Filed Certificate of Designation to establish Redeemable Convertible Preferred Stock with rights, preferences, and privileges.","evidence_excerpt":"The Company expects to file with the Secretary of State of the State of Delaware the Certificate of Designation attached hereto as Exhibit 3.1 and incorporated herein by reference.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850079/000119312523157992/0001193125-23-157992-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"82c9df61df30a7de498794a7ecda1f1e7b3a978e","claim":"Telesis Bio Inc. entered into Preferred Stock and Warrant Purchase Agreement with Novalis LifeSciences Investments II, L.P. and certain other investors valued at approximately $28.0 million (effective 2023-05-31).","evidence_excerpt":"On May 31, 2023, Telesis Bio Inc. (the “Company”) entered into a redeemable convertible preferred stock and warrant purchase agreement (the “Preferred Stock and Warrant Purchase Agreement”) with Novalis LifeSciences Investments II, L.P. (the “Lead Investor”) and certain other investors","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850079/000119312523157992/0001193125-23-157992-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Novalis LifeSciences Investments II, L.P. and certain other investors"},{"label":"Value","value":"approximately $28.0 million"},{"label":"Effective","value":"2023-05-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}